Experimental cell therapy for resistant lung cancer tested in tiny trial
Disease control
Terminated
This early-phase trial tested a new treatment called C-TIL051 for people with advanced non-small cell lung cancer that no longer responded to standard immunotherapy. The treatment involved taking immune cells from the patient's tumor, growing them in a lab, and infusing them back…
Phase: PHASE1 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC